Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Peresolimab in Healthy Participants
NCT05959109Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peresolimab in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 85 days, Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point at 85 days and 1 more. Started Jul 2023; status: completed.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05959109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959109.